* The 8 patients withdrew consent after being randomised (SIRT n=2, sorafenib n=6). According to French law, the data of these patients cannot be used in the analysis.
† Lung shunting (n=14), worsening disease (n=4), arterio-portal shunt (n=2), extra-hepatic disease (n=1), extra-hepatic uptake on MAA (n=1), no tumour uptake on MAA (n=1), technical reasons (n=3: no selective catheterisation n=2, iliac pseudo aneurism n=1).
‡ Pulmonary embolism (n=1), worsening disease (n=8), early death (n=2), technical reasons (n=5: arterio-portal shunt n=1, hepatic arterial thrombosis n=1, extra-hepatic uptake on MAA n=1, no tumour uptake on MAA n=1 and lung shunting n=1).
§ Additional patients have also not meet inclusion criteria (n=2) and received sorafenib instead of SIRT (n=1).
Vilgrain V et al. Lancet Oncol 2017; 18: 1624–36.